FLT3 and leukemia: To evaluate the anti-leukemia potency of CG-806, we compared the cytotoxic effects of the drug with other currently approved/available FLT3 and multi-kinase inhibitors in FLT3-mutated and FLT3-WT AML cell lines and patient samples.